The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Open accessAbstract
The sonic hedgehog (Shh) signaling pathway is a major regulator of cell differentiation, cell proliferation, and tissue polarity. Aberrant activation of the Shh pathway has been shown in a variety of human cancers, including, basal cell carcinoma, malignant gliomas, medulloblastoma, leukemias, and cancers of the breast, lung, pancreas, and prostate. Tumorigenesis, tumor progression and therapeutic response have all been shown to be impacted by the Shh signaling pathway. Downstream effectors of the Shh pathway include smoothened (SMO) and glioma-associated oncogene homolog (GLI) family of zinc finger transcription factors. Both are regarded as important targets for cancer therapeutics. While most efforts have been devoted towards pharmacologically targeting SMO, developing GLI-targeted approach has its merit because of the fact that GLI proteins can be activated by both Shh ligand-dependent and -independent mechanisms. To date, two SMO inhibitors (LDE225/Sonidegib and GDC-0449/Vismodegib) have received FDA approval for treating basal cell carcinoma while many clinical trials are being conducted to evaluate the efficacy of this exciting class of targeted therapy in a variety of cancers. In this review, we provide an overview of the biology of the Shh pathway and then detail the current landscape of the Shh-SMO-GLI pathway inhibitors including those in preclinical studies and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Mutations affecting segment number and polarity in Drosophila
Nüsslein-Volhard, C., & Wieschaus, E. (1980) · Nature · doi:10.1038/287795a0 · Cited by 4,370
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Hedgehog signaling in animal development: paradigms and principles
Ingham, P. W., & McMahon, A. P. (2001) · Genes & Development · doi:10.1101/gad.938601 · Cited by 2,985
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“Regorafenib (Stivarga) Bayer VEGFR1-3 [170] PDGFRβ FGFR-1 KIT RET B-Raf Metastatic Colorectal Cancer [171] Metastatic Gastrointestinal Stromal Tumors [172]”
BackgroundDemetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Cited by
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
Stem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Müller, H. L., Merchant, T. E., Warmuth-Metz, M., Martinez-Barbera, J.-P., & Puget, S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0125-9 · Cited by 515
A highlight on Sonic hedgehog pathway
Carballo, G. B., Honorato, J. R., de Lopes, G. P. F., & Spohr, T. C. L. D. S. E. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0220-7 · Cited by 460
Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
Lin, S., Chang, C., Hsu, C., Tsai, M., Cheng, H., Leong, M. K., Sung, P., Chen, J., & Weng, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14816 · Cited by 425
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
Natural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 259
Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
Liu, Y.-C., Yeh, C.-T., & Lin, K.-H. (2020) · Cells · doi:10.3390/cells9061331 · Cited by 253
Understanding the Molecular Genetics of Basal Cell Carcinoma
Pellegrini, C., Maturo, M., Di Nardo, L., Ciciarelli, V., Gutiérrez García-Rodrigo, C., & Fargnoli, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112485 · Cited by 242
Primary cilia and ciliary signaling pathways in aging and age-related brain disorders
Ma, R., Kutchy, N. A., Chen, L., Meigs, D. D., & Hu, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105607 · Cited by 114
Neuronal and astrocytic primary cilia in the mature brain
Sterpka, A., & Chen, X. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.002 · Cited by 80
Medulloblastoma: Molecular understanding, treatment evolution, and new developments
Liu, X., Ding, C., Tan, W., & Zhang, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107516 · Cited by 54
Hwang, D., Dismuke, T., Tikunov, A., Rosen, E. P., Kagel, J. R., Ramsey, J. D., Lim, C., Zamboni, W., Kabanov, A. V., Gershon, T. R., et al. (2021) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102345 · Cited by 53
Li, C.-L., Fang, Z.-X., Wu, Z., Hou, Y.-Y., Wu, H.-T., & Liu, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113616 · Cited by 46
RetractedSonic hedgehog signalling pathway contributes in age-related disorders and Alzheimer’s disease
Parashar, A., jha, D., Mehta, V., Chauhan, B., Ghosh, P., Deb, P. K., Jaiswal, M., & Prajapati, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102271 · Cited by 28
The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma
Sims, D., Maranyane, H. M., Damerell, V., Govender, D., Isaacs, A. W., Peres, J., & Prince, S. (2020) · Cancers · doi:10.3390/cancers12020501 · Cited by 13
Metadata
- Authors
- Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H.-W.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2016-02-15
- Volume
- 8
- Issue
- 2
- Pages
- 22
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2269814587
- Cited by
- 581
- References
- 168
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.